Holen Sie sich die Stockscreener-App
8.43
0.47%
-0.04
Handel nachbörslich:
8.43
Schlusskurs vom Vortag:
$8.47
Offen:
$8.45
24-Stunden-Volumen:
792.58K
Relative Volume:
0.62
Marktkapitalisierung:
$657.07M
Einnahmen:
$400.05M
Nettoeinkommen (Verlust:
$181.01M
KGV:
4.0156
EPS:
2.0993
Netto-Cashflow:
$194.58M
1W Leistung:
+1.57%
1M Leistung:
+12.10%
6M Leistung:
+18.40%
1J Leistung:
-34.14%
1-Tages-Spanne:
$8.31
$8.605
1-Wochen-Bereich:
$8.06
$8.745
52-Wochen-Spanne:
$6.125
$13.83
CorMedix Inc Stock (CRMD) Company Profile
Firmenname
CorMedix Inc
Sektor
Branche
Telefon
908-517-9500
Adresse
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ARGX, MRNA, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
8.43 | 641.48M | 400.05M | 181.01M | 194.58M | 2.0993 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-20 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-06-30 | Herabstufung | D. Boral Capital | Buy → Hold |
| 2025-06-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-03-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-13 | Eingeleitet | D. Boral Capital | Buy |
| 2024-08-26 | Eingeleitet | Rodman & Renshaw | Buy |
| 2023-08-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-02-17 | Eingeleitet | Needham | Buy |
| 2020-09-29 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-09-21 | Eingeleitet | Truist | Buy |
| 2019-12-18 | Eingeleitet | B. Riley FBR | Buy |
| 2019-03-26 | Bestätigt | H.C. Wainwright | Buy |
| 2018-12-06 | Eingeleitet | ROTH Capital | Buy |
| 2017-09-25 | Bestätigt | H.C. Wainwright | Buy |
| 2017-08-10 | Bestätigt | Rodman & Renshaw | Buy |
| 2017-05-05 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-11-11 | Bestätigt | FBR & Co. | Outperform |
| 2016-03-17 | Bestätigt | FBR Capital | Outperform |
| 2016-03-03 | Eingeleitet | FBR Capital | Outperform |
| 2015-11-16 | Bestätigt | ROTH Capital | Neutral |
| 2015-10-29 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2014-12-08 | Bestätigt | ROTH Capital | Buy |
| 2011-10-03 | Herabstufung | Maxim Group | Buy → Hold |
Alle ansehen
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
CorMedix Inc. (CRMD) Latest Stock News & Headlines - finance.yahoo.com
Wall Street Analysts Think CorMedix (CRMD) Could Surge 67.73%: Read This Before Placing a Bet - Yahoo Finance
Bank of New York Mellon Corp Takes Position in CorMedix Inc $CRMD - MarketBeat
CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge - Stocktwits
CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market - Stocktwits
The Technical Signals Behind (CRMD) That Institutions Follow - news.stocktradersdaily.com
Cormedix Stock Price Forecast. Should You Buy CRMD? - StockInvest.us
CorMedix Inc (NASDAQ: CRMD) Share Price, CRMD Stock News, CRMD Share Price & Updates - kalkine.ca
243,232 Shares in CorMedix Inc $CRMD Purchased by Empowered Funds LLC - MarketBeat
CRMD|CorMedix Inc|Price:8.430|Chg%:-0.040 - TradingKey
CorMedix (CRMD) COO holds 270K shares after cost-covering share withholding - Stock Titan
CorMedix will meet investors in Boston for a Wells Fargo chat - Stock Titan
BlackRock Inc. Acquires Shares of 6,324,111 CorMedix Inc $CRMD - MarketBeat
CorMedix (CRMD) Upgraded to Buy: Here's Why - Yahoo Finance
Equity award costs paid in stock at CorMedix (CRMD) - Stock Titan
CRMD's Growth Story Expands Beyond DefenCath Into New Trends - Eastern Progress
CorMedix (CRMD) Results at a Glance: EPS Exceeds Its Estimate in Latest Trading; Shares Move Lower 0.72% on the DayTech Earnings Analysis - vinanet.vn
CorMedix (CRMD) Q2 2026 Earnings Call Transcript - AOL.com
Wall Street Analysts Believe CorMedix (CRMD) Could Rally 65.96%: Here's is How to Trade - Yahoo Finance
CorMedix (CRMD) Momentum: Moves 0.12% Up to $8.18 in the Current Update; Range View: Traders Can Monitor the $7.77-$8.59 Range in Latest TradingETF Creation Redemption - vinanet.vn
CorMedix (CRMD) Price Action: Ends Up by 6.19% at $8.14 on the Day; Chart Reference: the Near-Term Reference Band Stretches From $7.73 to $8.55 in the Latest SessionReversal Setup Alerts - Vinanet
Research Analysts Set Expectations for CorMedix Q3 Earnings - MarketBeat
CRMD Q2 2026 Earnings: EPS of $0.29 Beats Consensus by 19.4%EPS Guidance Update - Vinanet
CorMedix: Durable Commercial Base, But 2027 Is The Real Test (NASDAQ:CRMD) - Seeking Alpha
CorMedix (NASDAQ:CRMD) Shares Up 7.3% on Analyst Upgrade - MarketBeat
FY2026 EPS Estimates for CorMedix Raised by HC Wainwright - MarketBeat
(CRMD) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
CorMedix Inc (CRMD) Stock News Today - TradingKey
CorMedix Stock Jumps on Strong DefenCath Sales - Sahm
Full Transcript: Cormedix Q2 2026 Earnings Call - Sahm
CorMedix (NASDAQ:CRMD) Shares Down 4.6%Here's Why - MarketBeat
Royal Bank Of Canada Issues Positive Forecast for CorMedix (NASDAQ:CRMD) Stock Price - MarketBeat
CorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says - marketscreener.com
CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains - The Globe and Mail
RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating - Moomoo
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
H.C. Wainwright reiterates CorMedix stock rating on strong quarter - Investing.com
H.C. Wainwright reiterates CorMedix stock rating on strong quarter By Investing.com - Investing.com India
H.C. Wainwright Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $13 - Moomoo
CorMedix (CRMD) Q2 2026 Earnings Call: Revenue Hits $101.9M, EBITDA Guidance Raised - TradingKey
CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
CorMedix Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
CorMedix Shares Surge 17% as Q2 Revenue Tops $100 Million, EBITDA Outlook Raised - finance.biggo.com
CorMedix Q2 2026 Earnings Call Transcript - MarketBeat
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $15 - Moomoo
CorMedix (CRMD) Surges 14.65% to $8.14 as Biotech Momentum Builds Toward ResistanceALMA Signal - Vinanet
CorMedix Shares Rise After Q2 Results, Guidance - marketscreener.com
CorMedix (NASDAQ:CRMD) Releases Earnings Results, Beats Estimates By $0.05 EPS - MarketBeat
CorMedix Q2 revenue hits $101.9M; DEFSEC up 92% YoY - scanx.trade
CorMedix Q2 Earnings Call Highlights - MarketBeat
CorMedix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Finanzdaten der CorMedix Inc-Aktie (CRMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):